Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 18, 2002

View Archived Issues

Cell therapy as a treatment for myocardial infarction and heart failure

Endo updates investors at healthcare conference

Squalamine enters clinical trials for fibrodysplasia ossificans progressiva

Generex's buccal morphine demonstrates proof of concept in phase I study

AtheroGenics aggressively developing lead compound

ProSorb formulation of pain medication enters pivotal trials

Activity and adequate safety demonstrated in phase II trial of Onconase in malignant mesothelioma

Orally and topically administered C5a antagonist effective in dermal immunoinflammatory reaction

Potent and selective ETA receptor antagonist potently lowers blood pressure in rats

Efficacy of novel mucosal vaccine delivery system described by RxKinetix in recent article

Corixa and Beaufour Ipsen collaborate on AnergiX.MG technology for myasthenia gravis

Oxford GlycoSciences, Medarex and Genmab in new initiative against cancer

Enbrel approved for treatment of psoriatic arthritis

Phase 2 Discovery to develop LY-156735 for sleep disorders

Risedronate receives approval in Japan

Alizyme's mucositis drug ATL-104 proves safe and well tolerated in phase Ia trial

Board recommends continuing phase III trial of Actimmune for IPF

Alliance looks to resume phase III program for Oxygent

Palonosetron completes phase III trials for CINV

New NK1 receptor antagonists described recently by Roche

Preparation and use of new thiourea NPY Y1 antagonists for eating disorders

Anticoagulants derived from phenylglycine at Roche

European scientists design triterpenoids which inhibit CDKs

MMP inhibitors and potential uses thereof reported by Aventis

Vertex researchers synthesize series of caspase inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...